These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

261 related items for PubMed ID: 36732125

  • 21.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 22. An epidemiological study of the susceptibility and frequency of multiple-drug-resistant strains of Pseudomonas aeruginosa isolated at medical institutes nationwide in Japan.
    Tsuji A, Kobayashi I, Oguri T, Inoue M, Yabuuchi E, Goto S.
    J Infect Chemother; 2005 Apr; 11(2):64-70. PubMed ID: 15856373
    [Abstract] [Full Text] [Related]

  • 23.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 24.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 25. [Antimicrobial susceptibility of phenotypically extended spectrum beta-lactamase producing Pseudomonas aeruginosa and Acinetobacter baumannii isolates].
    Metan G, Zarakolu P, Hasçelik G, Akova M.
    Mikrobiyol Bul; 2006 Apr; 40(1-2):23-8. PubMed ID: 16775953
    [Abstract] [Full Text] [Related]

  • 26. Ciprofloxacin-resistant Pseudomonas keratitis.
    Garg P, Sharma S, Rao GN.
    Ophthalmology; 1999 Jul; 106(7):1319-23. PubMed ID: 10406614
    [Abstract] [Full Text] [Related]

  • 27. An in vitro resistance study of levofloxacin, ciprofloxacin, and ofloxacin using keratitis isolates of Staphylococcus aureus and Pseudomonas aeruginosa.
    Kowalski RP, Pandya AN, Karenchak LM, Romanowski EG, Husted RC, Ritterband DC, Shah MK, Gordon YJ.
    Ophthalmology; 2001 Oct; 108(10):1826-9. PubMed ID: 11581056
    [Abstract] [Full Text] [Related]

  • 28.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 29.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 30. Activity of ceftolozane/tazobactam against a collection of Pseudomonas aeruginosa isolates from bloodstream infections in Australia.
    Henderson A, Tan E, McCarthy KL, Paterson DL.
    Pathology; 2018 Dec; 50(7):748-752. PubMed ID: 30392710
    [Abstract] [Full Text] [Related]

  • 31.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 32. Antimicrobial susceptibility of multidrug-resistant Pseudomonas aeruginosa isolated from drinking water and hospitalized patients in Jordan.
    Tarazi YH, Abu-Basha E, Ismail ZB, Al-Jawasreh SI.
    Acta Trop; 2021 May; 217():105859. PubMed ID: 33582141
    [Abstract] [Full Text] [Related]

  • 33.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 34. Review of resistance of ocular isolates of Pseudomonas aeruginosa and staphylococci from keratitis to ciprofloxacin, gentamicin and cephalosporins.
    Willcox MD.
    Clin Exp Optom; 2011 Mar; 94(2):161-8. PubMed ID: 21083760
    [Abstract] [Full Text] [Related]

  • 35. In vitro activity of clarithromycin in combination with other antimicrobial agents against biofilm-forming Pseudomonas aeruginosa strains.
    Kádár B, Szász M, Kristóf K, Pesti N, Krizsán G, Szentandrássy J, Rókusz L, Nagy K, Szabó D.
    Acta Microbiol Immunol Hung; 2010 Sep; 57(3):235-45. PubMed ID: 20870595
    [Abstract] [Full Text] [Related]

  • 36. Efficacy of sub-MIC level of meropenem and ciprofloxacin against extensive drug-resistant (XDR) Pseudomonas aeruginosa isolates of diabetic foot ulcer patients.
    Srivastava P, Sivashanmugam K.
    Infect Genet Evol; 2021 Aug; 92():104824. PubMed ID: 33774177
    [Abstract] [Full Text] [Related]

  • 37. The peculiarities of Pseudomonas aeruginosa resistance to antibiotics and prevalence of serogroups.
    Gailiene G, Pavilonis A, Kareiviene V.
    Medicina (Kaunas); 2007 Aug; 43(1):36-42. PubMed ID: 17297282
    [Abstract] [Full Text] [Related]

  • 38. Does ivacaftor interfere with the antimicrobial activity of commonly used antibiotics against Pseudomonas aeruginosa?-Results of an in vitro study.
    Millar BC, Rendall JC, Downey DG, Moore JE.
    J Clin Pharm Ther; 2018 Dec; 43(6):836-843. PubMed ID: 29959786
    [Abstract] [Full Text] [Related]

  • 39. Comparative activity of newer β-lactam/β-lactamase inhibitor combinations against Pseudomonas aeruginosa isolates from US medical centres (2020-2021).
    Sader HS, Mendes RE, Arends SJR, Carvalhaes CG, Shortridge D, Castanheira M.
    Int J Antimicrob Agents; 2023 Apr; 61(4):106744. PubMed ID: 36738849
    [Abstract] [Full Text] [Related]

  • 40. [Antimicrobial susceptibility of Pseudomonas aeruginosa isolated at Kochi Municipal Central Hospital in the last 3 years].
    Nasu Y, Abe M, Ono N, Araki M, Horimi T, Takahashi I.
    Jpn J Antibiot; 2004 Oct; 57(5):438-48. PubMed ID: 15655905
    [Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 14.